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Acetate and bicarbonate fluctuations and acetate intolerance
during dialysis
MARK D. PAGEL, SUHAIL AHMAD, JOSEPH E. Vizzo, and BELDING H. SCRIBNER
Acetate and bicarbonate fluctuations and acetate intolerance during
dialysis. Plasma bicarbonate losses during acetate dialysis were pre-
vented by using a combination of acetate and bicarbonate in the
dialysate. In 21 patients who were treated with combination dialysate,
the fall in mean blood pressure (MBP), and frequency of symptoms, and
post-dialysis task performance were all similar to that observed during
dialysis with acetate alone. Furthermore, dialysis performed with
bicarbonate dialysate resulted in significantly smaller MBP drops,
fewer symptoms, and an improved task performance compared to
either an acetate or a combination dialysis. These findings indicate that
the presence of acetate, rather than a bicarbonate loss, was responsible
for the patients' intolerance to acetate dialysis. Patients symptomatic
on acetate dialysis had a similar ultrafiltration rate, weight loss, MBP
drops, and postdialysis serum acetate levels; they were similar in age
and weight to symptom-free patients. Thus, the toxic effect of acetate
was not related to serum acetate level. There was no difference in
bicarbonate dialysis between patients with symptoms on acetate and
the symptom-free patients in reference to MBP drops and task perform-
ance. This finding suggests that symptomatic patients were not simply
less tolerant to the process of dialysis, but differed from symptom-free
patients in their response to the presence of acetate.
Fluctuation de l'acétate et du bicarbonate, et intolerance a l'acétate
pendant Ia dialyse. Les pertes en bicarbonates plasmatiques au cours de
dialyses avec l'acétate ont éte prévenues en utilisant un mélange
d'acCtate et de bicarbonate dans Ic dialysat. Chez 21 malades dialyses
avec ce mélange, Ia chute de Ia pression artérielle moyenne (PAM), Ia
frequence de symptômes, et Ia performance a l'effort après Ia dialyse
étaient similaires a ce qu'elles étaient lors des dialyses contre de
l'acCtate seul. De plus, Ia dialyse contre un dialysat avec du bicarbonate
s'accompagnait de chutes de PAM significativement plus faibles, de
moms de symptômes, et améliorait Ia performance a l'effort par rapport
ala dialyse avec acetate ou avec Ic melange. Ces résultats indiquent que
c'est Ia presence d'acétate, plus que Ia perte de bicarbonate qui est
responsable de l'intolérance des malades lors d'une dialyse avec
acetate. Les malades symptomatiques lors des dialyses a l'acétate
avaient des taux d'ultrafiltration, une perte de poids, des chutes de
PAM et des taux d'acétate plasmatique postdialyse identiques a ceux
des malades asymptomatiques et étaient d'âge et de poids égaux. Ainsi,
Ia toxicitC de l'acétate n'était pas en rapport avec Ia concentration
d'acétate sérique. Dans Ic cas des dialyses avec bicarbonate, il n'y avait
pas de difference entre les malades symptomatiques avec l'acétate et les
malades asymptomatiques, qu'il s'agisse des chutes de PAM ou de Ia
performance a l'effort. Ce fait suggère que les malades symptomatiques
n'étaient pas simplement moms tolérants a Ia dialyse en soi mais
différaient des malades asymptomatiques par leur reponse a Ia presence
d'acétate.
acetate to bicarbonate fast enough to replace bicarbonate losses
into the dialysate. When bicarbonate dialysate replaced acetate,
patients reported significantly fewer symptoms, and significant
increases in the rates of ultrafiltration were tolerated [I]. Yet, it
was still unclear whether or not the symptoms during acetate
dialysis were related to elevated serum acetate levels or to the
decreased bicarbonate concentrations. Our study was under-
taken to clarify these issues. Bicarbonate losses during acetate
dialysis were prevented by using a combination of acetate and
bicarbonate anions in the dialysate. The patient's symptoms
during combination dialysis were then compared with their
symptoms during dialysis containing only acetate and during
dialysis with only bicarbonate.
Methods
Twenty-three stable maintenance dialysis patients undergo-
ing treatment from both the University of Washington Research
Dialysis Unit, the Northwest Kidney Center (Seattle), and the
Seattle Veterans Administration Hospital participated in the
study. All dialyses for our study were performed at the Univer-
sity's Research Dialysis Unit after obtaining informed consent.
The 14 female and 9 male patients ranged in age from 28 to 75
(Mean value = 54 + 14 SD).
Patients with a known history of cardiac or respiratory
problems, or with diabetes mellitus were excluded from the
study. Two patients receiving antihypertensive medication
(propranolol) participated in the study, but their data were not
included in this paper; thus 21 patients are included in the
analyses.
Each patient was dialyzed three times: once each with 38
mEq/liter acetate (A), 35 mEq/liter bicarbonate (B), and a
combination bath containing 38 mEq/liter acetate and 10 mEq/
liter bicarbonate (C). Each dialysate bath contained 3.5 mEq/
liter calcium, 140 mEq/liter sodium, and potassium was added
as needed. The total chloride content was 102, 105, and 92
mEq/liter for the A, B, and C dialysates, respectively. Prelimi-
nary in vivo testing indicated that the 10 mEq/liter of bicarbon-
ate in the combination dialysate in conjunction with the expect-
ed bicarbonate generation from acetate metabolism would
produce serum bicarbonate levels similar to B dialysis. Thus,
We have reported previously that patients who were symp-
tomatic on acetate dialysis typically showed substantial reduc-
tion in serum bicarbonate during dialysis, high serum acetate
levels, and large acid-base fluctuations [1]. These results sug-
gested that the symptomatic patients were not converting
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the C dialysate was designed to reproduce the acetate levels of
A dialysate while maintaining the serum bicarbonate at levels
like those of bicarbonate dialysis.
The three types of dialyses were randomly ordered, and the
patients were unaware of the type of dialysate. The patients
were dialyzed for four hours on a C-Dak 1.8 m2 dialyzer
(Cordis-Dow). Blood flow was maintained at 200 ml/min and
dialysate flow at 500 ml/min.
Unlike the previous study [1], it was not a goal of our present
study to demonstrate differences in tolerance to rapid ultrafil-
tration. As a result, rates of ultrafiltration which were custom-
ary for each patient were used.
Fistula blood samples were drawn from the arterial line just
before dialysis and every hour during dialysis for bicarbonate,
acetate, and pH measurements. All samples were handled
anaerobically and processed promptly on an IL 113 blood gas
apparatus. Plasma bicarbonate was measured by titration [2],
and serum acetate was measured by the enzymatic method [3].
The Choice Reaction Time (CRT) test was taken immediately
before and after each dialysis. The CRT measures in millisec-
onds the time needed to make a decision about the color of a
flashing panel. The CRT is widely used in the behavioral
sciences to study stimulus recognition models [4]. It was
included as an objective measure of the patients' ability to
maintain sustained concentration, and it was hypothesized to
vary with the patients' feelings of well being.' The average of 24
trials is taken at each test session to insure reliability. Patients
also filled out a symptom check list after each dialysis to report
episodes of nausea, vomiting, and headache. Blood pressure
was measured before dialysis and approximately at 30-minute
intervals throughout dialysis.
Results
Mean levels of plasma bicarbonate, acetate, and pH values
during dialysis are shown in Figures 1 to 3 (bars indicate 1
SEM) 2
Plasma bicarbonate (Fig. 1). Plasma bicarbonate levels dur-
ing combination (C) dialysis were maintained successfully at
levels similar to those seen on bicarbonate (B) dialysis. Predial-
ysis bicarbonate levels for B dialysis were approximately 0.8
mEq/liter higher than for C dialysis. This difference could not
be justified by the order of treatments and is thought to
represent chance fluctuation. Bicarbonate levels for B and C
were not different from each other during dialysis when adjust-
ed for predialysis levels. As expected, bicarbonate levels on A
dropped significantly in the first hour (P < 0.001), and hourly
bicarbonate levels during acetate (A) dialysis were significantly
lower than during B and C (all differences, P < 0.004).
pH (Fig. 2). Blood pH levels on B and C were significantly
higher than on A at 1, 2, 3, and 4 hours (all differences, P <
0.004). The pH level measured during C dialysis was the same
for B dialysis.
Serum acetate (Fig. 3). Serum acetate levels were measured
only for A and C dialyses, and they were not different at any
time. The patients' postdialysis acetate levels on A were highly
correlated with their postdialysis acetate levels on C (r = 0.87,
P < 0.001). Postdialysis values ranged from 2.08 to 12 mEq/liter
on A (Mean value = 6.34 3.10) and from 1.2 to 13.6 mEqfliter
on C (Mean value = 6.63 3.13). The postdialysis acetate level
was correlated negatively with the postdialysis bicarbonate on
A (r =
—0.75, P < 0.001), indicating that a greater acetate
metabolism was associated with a greater bicarbonate genera-
'From informal observation we found that the CRT is stable over a
period of time for individual patients. The CRT appears to fluctuate
with patients' reports of how they feel after dialysis. It is not necessarily
related to events which occur during dialysis (for example, blood
pressure change) unless these events produce effects which continue
after dialysis (for example, nausea and a headache).
2All statistical tests between correlated groups were made with the
Wilcoxon test; the Mann Whitney test was used for all independent
group comparisons (51. The tests were chosen because they do not
make any assumptions about the distribution of the raw scores, unlike
the Student's t test [5]. Strictly speaking, the tests do not measure mean
differences between groups, but means and standard deviations are
reported for interpretability. All significant comparisons, however,
were also significant when the Student's t distribution was assumed to
underly the data.
Blood pressure, ultrafiltration rates, and weight loss
Blood pressure (BP) changes among the three treatments
were evaluated by comparing the predialysis blood pressure
with the lowest blood pressure during the dialysis (Table 1). As
evidence of the stability of these measures, ongoing systolic BP
scores for A, B, and C dialyses were highly intercorrelated (F,
average correlation = 0.82, range = 0.78 — 0.86, P <0.001), as
were the ongoing diastolic pressures (F = 0.69 range 0.65 —
0.75, P < 0.002). The ongoing average BP was comparable
among treatments, but the low BP values during A and C
dialyses were significantly lower than during B (low systolic BP
on A and C versus B, P < 0.01, low diastolic BP on A and C
versus B, P < 0.04). Table 1 presents the predialysis and lowest
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Fig. 1. Plasma bicarbonate changes during dialysis. The letter a
represents: acetate < bicarbonate, and acetate < combination, P <
0.004. See Results section in text.
tion.
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Fig. 2. Changes in blood pH during dialysis. The letter a represents
acetate < bicarbonate, and acetate < combination, P < 0.004. See
Results section in text.
mean arterial BP (MBP) values. The fall in MBP, defined as the
ongoing MBP minus the lowest MBP was significantly larger on
A and C than on B (A versus B, P < 0.04; C versus B, P <
0.010).
Table 1 also presents the ultrafiltration rates and total weight
loss. Ultrafiltration rate (UFR) was calculated as the number of
kilograms of body wt lost per hour of actual ultrafiltration. The
UFR was highly intercorrelated among the treatments (F =0.80,
range = 0.73 — 0.84, P <0.001), and the average UFR's did not
differ. As expected, weight loss followed the pattern of UFR (F
= 0.77, range = 0.73 — 0.80, P < 0.002). Average weight loss on
C was statistically less than on B (P < 0.035), but only differed
by 0.27 kilograms.
Although the mean UFR was the same and highly intercorre-
lated between A and B dialyses, there was a greater tolerance to
high ultrafiltration rates on B dialysis than on A. Figure 4 plots
the regression line of fall in MBP against UFR, separately for A,
B, and C dialyses. The lines show a large expected difference in
MBP drop for comparable rates of ultrafiltration during the
three treatments3.
Symptoms and performance task scores
The frequency of headache, nausea, and vomiting was re-
corded from the symptom questionnaires each patient filled out
following dialysis. Table 2 presents these data for each treat-
ment. Overall nearly twice as many symptoms were reported
3Because of the repeated measures (that is, each patient received all
treatments), the conventional test of the difference between the slopes
of the lines is inappropriate. When the patients were put into high and
low UFR groups (median split), however, it was found that the average
BP drop was greater on A and C compared to B, in the high group (P <
0.01) but not in the low group.
Hours on dialysis
Fig. 3. Serum acetate levels during dialysis.
for the A and C dialyses than were reported for B, (A = 23, C =
25 versus B = 13, P < 0.03). However, nausea accounted for
nearly all of the differences.
Reaction-time scores were evaluated for each treatment by
computing the difference between the post- and predialysis
average scores for each patient. Thus, large positive numbers
represent a substantial slowing of reaction time (measured in
milliseconds) from pre- to postdialysis. Slowing of reaction time
was highly intercorrelated among the treatments (F =0.71 range
= 0.63 — 0.77, P < 0.002). From Table 2, average reaction time
slowed significantly more following A and C dialyses than after
B dialyses (A versus B, P < 0.03, C versus B, P < 0.01).
Reaction times following C dialysis were also significantly
slower than after A. The method of partial correlation [61 was
used to test whether or not this finding is related to the presence
of both elevated acetate and bicarbonate (or pH) during the
combination dialysis. Partial correlation statistically holds con-
stant the level of one variable while assessing the relationship
between two other variables. When the effects of either pH or
bicarbonate were controlled in this way, the difference between
A and C reaction-time scores disappeared. The partialed A and
C scores, however, were both still larger than the scores on
bicarbonate dialysis.
The 10 patients who reported nausea during acetate dialysis
were compared to the 13 who did not report nausea (for
reliability, similar symptoms scoring on C dialysis showed that
7 out of the 10 incidences of nausea were reported by those who
also experienced nausea on A). It can be seen in Table 3 that
these two patient groups did not differ on any of the treatments
with respect to MBP changes, UFR, and weight loss. Age, body
weight, and hematocrit also did not differ, There was a slight
but not significant tendency for those with nausea to have
higher acetate levels (P = 0.19) and only 3 of the 10 reporting
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Table 1. Average weight loss, ultrafiltration rates, and blood pressure changes during dialysis
Acetate (A) Bicarbonate (B) Combination (C)
Ongoinga Lowesta Ongoing Lowest Ongoing Lowest
Blood pressure
Systolic 150.2 34.5 119.4 27.7" 151.7 27.6 129.2 28.7 150.3 28.5 115.9 22.1"
Diastolic 79.2 18.0 6.4.4 20.9' 77.9 11.0 69.0 12.1 81.1 18.0 62.9 13.8'
Mean BP 102.0 22.6 82.7 22.5" 102.5 15.8 89.1 17.0 104.1 19.9 80.5 15.3"
MBP change 20.2 17.0' 13.4 14.1 23.6 15.6"
Wt loss, kg 1.55 0.93 1.59 0.80 1.32 0.66
UFR, kg/hr 0.49 0.26 0.49 0.24 0.43 0.23
"Ongoing" measurements were taken just prior to connecting the patient; "lowest" refers to the lowest blood pressure reading during dialysis.
b A or C vs. B, P <0.01.
A or C vs. B, P< 0.04.
d A or C vs. B, P < 0.02.
Abbreviations: MBP = mean blood pressure; UFR = ultrafiltration rate.
nausea were males. Following A and C dialyses, patients who
reported nausea experienced more of a slowing of reaction time
than those not reporting nausea (Table 3); however, there was
no difference between these groups after B dialysis.
Acetate levels and patient characteristics
C The relationships reported in this section pertain to acetate
dialysis only. The results on combination dialysis, however,
were the same. Acetate levels at the end of A dialysis were
significantly related to body weight (r = 0.69, P < 0.002), and
sex (Mean value = 7.9 0.8 females, Mean value = 3.93, 0.5
males, P < 0.01) but not to age (r = 0.12). Partial correlation [6]
suggested that the relationship between sex and the acetate
level was secondary to body weight; that is, the correlation
between body weight and acetate level was still significant
when the effects of sex were held constant (r = 0.35, P <0.05),
but when acetate levels and sex were analyzed, holding body
weight constant, the difference between males and females
disappeared. Increasing acetate levels were associated with
increased deterioration in CRT scores (r = 0.41, P < 0.025).
Acetate levels at the end of dialysis were negatively correlat-
ed with UFR (r = —0.42, P < 0.025), indicating less ultrafiltra-
tion the higher the acetate level and with weight loss (r = —0.55,
P < 0.007). The acetate level did not significantly correlate with
the fall in MBP (r = —0.15) nor with hematocrit (r = —0.01).
Discussion
Table 2. Symptoms and performance task scores during dialysis
Frequency of
symptoms
Acetate
(A)
Bicarbonate
(B)
Combination
(C)
Nausea 10 2 10
Headache 11 11 14
Vomiting 2 0 1
Total 23a 13 25b
Reaction time change,
msec' 29.3a 9.1 40.9b
a A vs. B, P < 0.05.
"C vs. B, P < 0.01.
Measured as preminus postdialysis reaction-time score on choice
reaction-time task (see text for description).
We have reported previously that some patients experience
hypotension, headache, nausea, and vomiting during acetate
dialysis, and show postdialysis performance task decrements
[1]. These symptoms were reduced significantly when the
patients were dialyzed against the bicarbonate [1]. It was not
clear from the study, nor from other clinical studies of acetate
dialysis, whether or not the symptoms were related to acetate
influx from the dialysate [7—9] or to the loss of bicarbonate also
seen during acetate dialysis [1, 9].
The present data show that use of a combination of acetate
and bicarbonate dialysate successfully prevented bicarbonate
loss during dialysis and maintained the patients' blood bicar-
bonate at levels comparable to bicarbonate dialysis. Thus, the
finding of a significantly higher incidence of symptoms and
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Fig. 4. Regression line of fall in mean blood pressure versus rate of
ultrafiltration. (See footnote 3.) Letters used are defined: b, slope
different from zero, P < 0.050; c, slope different from zero, P < 0.001;
d, slope different from zero, P < 0.015.
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Table 3. Characteristics, symptoms, blood pressure , and task performance of symptomatic and asymptomatic patients
Symptomatic patientsa Asymptomatic patients
A B C A B C
Wt loss, kg
UFR kg/hr
MBP change
CRT change,
msecb
1.52 0.93
0.52 0.28
19.9 18.0
42.6 28.0c
1.53 0.81
0.52 0.23
12.3 9.1
23.0 17.9
1.39 0.66
0.45 0.23
28.6 16.0
55.6 34,5d
1.58 0.98
0.47 0.25
16.9 12.5
9.3 31.9
1.63 0.83
0.47 0.25
9.8 5.9
—2.3 47.6
1.26 0.68
0.42 0.25
21.4 15.4
25.0 45.2
Body wt, kg
Age
Hematocrit
Acetate level,
mEq/liter
62.1 8.1
57.1 9,6
29.1 5.3
7.7 3.2
62.2 11.7
52.5 16.4
27.1 10.7
5.9 2.9
Symptomatic patients experienced nausea during acetate dialyses; asymptomatic patients had no nausea.
b Defined in Table 2.
Symptomatic group significantly different from asymptomatic group, P = 0.05.
d Symptomatic group vs. asymptomatic group, P = 0.06.
Serum acetate level at end of dialysis (4 hrs).
Abbreviations used are defined: CRT, Choice Reaction Time test; MBP, mean blood pressure; UFR, ultrafiltration rate; A, acetate dialysis
group; B, bicarbonate dialysis group; C, combination dialysis group.
larger drops in MBP on combination dialysis compared to
bicarbonate dialysis clearly show that the occurrence of symp-
toms and hypotension was not due to bicarbonate loss. Further-
more, the similar frequency of symptoms, incidence of hypo-
tension, postdialysis reaction times, and blood acetate levels on
the combination and acetate dialyses implicate acetate in the
pathogenesis of the dialysis-related problems.
Intradialytic pH fluctuations [1, 9] and blood osmolar
changes [10] have also been suggested as causes of dialysis
symptoms. In our study, acidosis was corrected consistently,
even during acetate dialysis, and bicarbonate dialysis, despite
producing a high pH level, was associated with a significantly
less MBP drop, fewer symptoms, and less deterioration in
reaction-time scores than acetate or combination dialysis; thus,
alkalosis also did not contribute substantially to the symptoms.
Bergstrom has reported that blood osmolar changes are an
important cause of hypotension during dialysis [10]. Previously,
we found that changes in blood osmolarity during dialysis with
our acetate dialysate were equivalent to the bicarbonate dialy-
sate [1]. Thus, in this study the difference between acetate and
bicarbonate dialyses should not be the result of osmolar
changes.
The role of acetate levels in the development of symptoms is
controversial with some studies reporting that symptoms and
incidence of hypotension increase with rising acetate levels [7,
11], whereas others find no relation between symptomatology
and acetate levels [8, 12]. That the relationship seems to depend
on other factors as well suggests that the issue has been poorly
defined. Thus, when the ultrafiltrate was replaced by normal
saline [9], or 1.0 — 1.6 m2 surface area dialyzers were used [8],
no relationship between acetate and hypotension was found.
Yet with large surface area dialyzers [1] or rapid weight loss [1,
7] on acetate dialysis, hypotension has been found. Further
evidence for the role of ultrafiltration is found in Figure 4. With
21 patients and 1.8 m2 dialyzers, the rate of ultrafiltration on
acetate dialysis varied from 0.06 to 1,04 kg/hour. Although only
five episodes of hypotension ( 100 mm Hg systolic BP)
occurred, the fall in MBP tended to increase with increasing
ultrafiltration on acetate dialysis, but similar ultrafiltration on
bicarbonate (range = 0.0 — 0.94 kg/hour) did not produce the
same trend. These results suggest, among other things, that the
incidence of frank hypotension is not a sensitive indicator of the
effects of acetate unless UFR is held constant.
Still some studies report at least one patient with an acetate
level greater than 10 to 12 mEq/liter who is symptom free; this is
taken as evidence against a linear relationship between increas-
ing acetate levels and increasing blood pressure swings or
symptoms [7, 8]. Bearing in mind the limitations imposed on
such conclusions by the above factors, this may in fact be true.
Although in the present study acetate levels of 10 to 12
mEq/liter appeared to have a high probability of producing
symptoms, for other patients only 3 to 5 mEq/liter of acetate
during dialysis were associated with significant symptomatol-
ogy. The point is that factors less obvious than dialyzer size,
absolute acetate level, or the variables presented in Table 3 may
moderate the acetate-symptom relationship. Experimental de-
signs that manipulate or carefully control factors like ultrafiltra-
tion rate and dialyzer size are needed before definitive relation-
ships between acetate level, symptoms, and important patient
variables can be expressed.
Unlike our earlier study [1], the present study was not
designed to test improved blood pressure regulation with bicar-
bonate dialysis. Ultrafiltration rates high enough to produce
large blood pressure swings on acetate, but which were tolerat-
ed when bicarbonate was used [1], were purposely avoided in
this study. Therefore, the significantly smaller drops in blood
pressure and the greater tolerance to ultrafiltration during
bicarbonate dialysis were somewhat surprising (Table 1, Fig. 4).
Interestingly, improvement in symptoms when the patients
were dialyzed against bicarbonate was independent of the
improved blood pressure control. That is, 10 of 23 patients who
reported nausea during acetate dialysis did not differ from those
who did not report nausea, in weight, age, hematocrit, acetate
level, blood pressure changes, ultrafiltration rate, or weight
loss. That the patients who reported nausea during acetate
dialysis did not report more symptoms than their relatively
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symptom free counterparts when both were dialyzed on bicar-
bonate suggests that there are some patient characteristics
which result in acetate intolerance independent of its concentra-
tion in the blood. Prevailing notions of the effects of acetate,
including a putative cardiac depressant effect [12, 13], vasodila-
tion l4, 15], increased cardiac oxygen demand and/or hypoxe-
mia [16], fail to account for patient individual difference varia-
bles which seem to make some patients especially sensitive to
acetate. Future research should be directed at identifying the
predictors of acetate intolerance.
Reprint requests to Dr. M. D. Pa gel, Division of Kidney Diseases,
Room 11, Department of Medicine, University of Washington School of
Medicine, Seattle, Washington 98195, USA
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